PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...
Claims of differential treatment effects were largely rated as “low credibility” or “very low credibility.” Subgroup analyses in cancer trials may not be credible, and their results should be ...
Alternating neoadjuvant gemcitabine-nab-paclitaxel (GnP) and nal-irinotecan, 5-fluorouracil and folinic acid (nal-IRI) regimens in resectable (R) and borderline resectable (BR) pancreatic cancer (PC): ...
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver ...
Please provide your email address to receive an email when new articles are posted on . SEATTLE — The effects of aflibercept treatment in the three arms of the PULSAR study were not affected by ...
Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF injections resulted in stable mean visual acuity that was equal to or higher ...
Panelists discuss how emerging evidence from first-line therapy trials continues to demonstrate the superiority of quadruplet over triplet regimens, with the CEPHEUS subgroup analysis confirming that ...
Clearside Biomedical, Inc. has announced the presentation of two subgroup analyses from its ODYSSEY Phase 2b clinical trial at the Angiogenesis, Exudation, and Degeneration 2025 meeting. The trial ...
In oncology drug development, biomarker-driven studies are pivotal, enabling the selection of patient populations most likely to benefit from specific therapeutic interventions. These studies have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results